FierceBiotechOriginal article
{"a":[{"_":"Prime wins patent fight with Beam to continue work on AATD gene editing therapy","$":{"href":"/biotech/prime-wins-patent-fight-beam-can-continue-work-aatd-gene-editing-therapy","hreflang":"en"}}]}
Patent ExpirypositivePositive
AI Analysis
Summary
Prime Medicine won a patent dispute with Beam Therapeutics, with adjudicators ruling it did not violate their agreement and can continue developing its lead gene editing therapy for alpha-1 antitrypsin deficiency.
Outcome Details
Patent panel ruled Prime Medicine did not violate agreement with Beam Therapeutics and can continue developing lead asset for AATD gene editing therapy
Importance:6/10
Sentiment:
0.80
patent disputegene editinglegal victoryAATDBeam TherapeuticsPrime Medicine
Related Companies
Read the original article
Published by FierceBiotech on July 8, 2026 11:08 AM